In chronic respiratory diseases, bronchitis expansion is very common in clinical diagnosis and treatment, but it is very easy to be ignored by patients. Previously, due to the lack of inhaled antibiotics in China, the treatment progress for the stable period of branch expansion disease has stagnated, bringing a heavy burden to patients, the medical system, and the society.
Tobramycin inhalation solution independently developed by Health yuan is a modified new drug developed for the high prevalence of branch expansion and the lack of clinical drugs in China. By changing the route of administration, from intravenous injection to topical inhalation, it is increasing the local effective drug concentration in the lungs while avoiding systemic toxicity and significantly reducing the risk of drug resistance, which is suitable for long-term maintenance therapy. The launch of tobramycin inhalation solution (®) has filled the gap in the inhalation treatment of Chinese clade expansion patients with Pseudomonas aeruginosa infection, and is an important breakthrough in the field of respiratory diseases.
Yesterday (November 10), Health Pharmaceutical Group "developed 2022 for Chinese patients" 2022, which was held simultaneously in Shenzhen, Shanghai and Beijing, both online and offline. Yu Xiong, president of Health Pharmaceutical Group, said that in recent years, the incidence and prevalence of branches have been increasing year by year, especially Chinese patients. Kencoto ® is an inhaled antibiotic specially developed for Chinese patients. It is the first aerosolized inhalation antibiotic used in the treatment of bronchiectasis in China. It is suitable for bronchiectasis, infection control and improvement of symptoms in adults with pulmonary Pseudomonas aeruginosa infection. The successful launch of Jianto ® will change the current situation of the field of atomization inhalation treatment for patients in China, provide more support for patients and improve the quality of life of patients.
Tobramycin inhalation solution was approved based on a confiridated phase III clinical trial, which is the first randomized, double-blind, national multicenter, large sample size clinical study on bronchiectasis in China. The clinical trial under the auspices of the academician zhong, the global initiative double clinical efficacy research end: bacterial load change and branch patients with quality of life score, and obtained the world's first double positive significant efficacy conclusion, and good safety, for the drug listed in our country provides a solid and reliable data support.
Zhu Baoguo, chairman of Health Yuan Pharmaceutical Group, said at the listing meeting that Health Yuan will give full play to its advantages, promote its own strengths, and continue to focus, to make more contributions to the treatment of respiratory diseases in China.
In recent years, inhalation preparations have been one of the key layout fields of Health yuan. 7 varieties of inhalation preparations and 11 products have been approved for the market, and more than 30 research projects are listed. The continuous expansion of inhalation preparation products matrix has further consolidated its position of "the leader of domestic inhalation preparations track".
